whereas, with four doubtful exceptions, the test was never positive in patients in whom the antibody had not been recently acquired. In short, in this population infectious mononucleosis accompanied by a positive Paul-Bunnell test was an entity associated with the development of EB virus antibody. On the other hand, cases resembling infectious mononucleosis but with a negative Paul-Bunnell test may be caused by a variety of agents.
A differing virological origin for cases of infectious mononucleosis with a positive Paul-Bunnell test and for cases with very similar clinical and haematological features but in whom the Paul-Bunnell test is negative goes far to explain the differences that have been reported between such positive and negative cases. These differences include incubation period, the age groups mainly affected, infectivity, and the occurrence of outbreaks (Hobson et al., 1958; Hoagland, 1967; Finch, 1969) .
Our thanks are due to Sir Austin Bradford Hill, who read the draft and made many helpful comments. We also wish to record our appreciation of the co-operation of the students, and of the help given by nursing and clerical staff of the university and college health centres.
Introduction
Infectious mononucleosis, as well as a number of other viral diseases, can be associated with thrombocytopenia of all grades (Ackroyd, 1949; Hudson et al., 1956 ). Asymptomatic thrombocytopenia is common (Carter, 1965; Cantow and Kostinas, 1966) , but thrombocytopenic purpura occurs only as a rare complication (Sharp, 1969) . The pathogenesis of virus-associated thrombocytopenia is unknown but may involve several mechanisms.
This study shows that abnormal platelet function is common in uncomplicated infectious mononucleosis, and it is suggested that these abnormalities reflect platelet damage which may predispose to premature platelet destruction. Cronkite (1950) . Platelet factor III availability was determined by incubation of platelet-rich plasma with kaolin at 37°C, with assay of platelet coagulant activity released at 1, 5, 10, and 20 minutes, and expressed as reduction in the Stypvencalcium time after 20 minutes' incubation (Spaet and Cintron, 1965; Hardisty and Hutton, 1965) . Platelet factor IV (antiheparin factor) was determined by prolongation of the thrombin time in the presence of heparin by platelet-rich plasmna (Niewiarowski and Thomas, 1969) .
Platelet aggregation was studied by a modification of the method of Born (1962) and O'Brien (1962) . Aggregating agents and their final concentrations were: adenosine diphosphate (ADP) 5 x 10-6M, adrenaline 5 x 10-6M, thrombin 0 1 unit/ml, and ristocetin 1 mg/ml. (Ristocetin is an antibiotic withdrawn from use because of the high incidence of thrombocytopenia, and found to be a useful aggregating agent in assessing platelet function (Howard and Firkin, 1971) .) Aggregation was measured as the maximal change in optical density caused by aggregate formation, expressed as a percentage of the optical density difference between platelet-rich and platelet-poor plasma. Tests of platelet aggregation were performed at a platelet concentration of 280,000/mm3 and at a temperature of 37°C. Platelet-poor plasma from five patients with platelet defects was tested for its ability to inhibit aggregation of normal platelet-rich plasma with ADP or ristocetin. Normal plateletrich plasma (1-5 ml) was incubated with 0 5 ml of patient's or normal platelet-poor plasma for 30 minutes at 37°C. ADP or ristocetin was then added and the optical density change measured, as above.
Antiplatelet antibodies were assessed by antibody-kaolininduced platelet factor III release. Details of this technique are to be published . In brief, the globulin fraction from a patient's serum is incubated with normal plateletrich plasma (platelet count 400,000/mm3) at 37°C for 30 minutes. The one-minute Stypven-calcium clotting time is determined after the addition of kaolin and compared with clotting times obtained with control globulin fractions. A test is considered to be positive for antiplatelet antibody when the clotting time is reduced by more than four seconds, compared with controls, on at least two separate occasions. This test is positive in 6500f of adult patients with idiopathic thrombocytopenic purpura and is negative in non-immunological thrombocytopenia. Fibrinogen degradation products were determined by haemagglutination inhibition (Merskey et al., 1969) .
Results
Platelet counts were normal in all patients. Fourteen had abnormal platelet aggregation; 11 had reduced aggregation with ADP and 13 with ristocetin (see Table) . Impaired aggregation with adrenaline and thrombin is more difficult to assess because of the wide normal range and the finding that some normals do not aggregate with adrenaline. In our laboratory 150O of normals did not aggregate with adrenaline, and these have been excluded in calculating the normal range. This figure is similar to that found by other workers (Logan et al., 1971) . However, only four patients aggregated within this range with adrenaline, indicating a probable reduced response to this agent. Variation in platelet aggregation with thrombin was also considerable but in 20 control subjects all had greater than 20% aggregation. As only five patients had greater than 647 20% aggregation with thrombin, aggregation was probably also impaired with this agent.
All eight patients tested had impaired platelet factor IV release, and four had reduced platelet factor III availability. Convalescent platelet function was normal in the six patients tested. The mean platelet count of these patients in the acute stage (214,000/mm3) was less than that in convalescence (267,000/mm3) (P <0 05). Platelet-poor plasma from five patients, all of whom had reduced aggregation with ADP and ristocetin, did not inhibit aggregation of normal platelet-rich plasma with either of these agents when compared with the effect of normal platelet-poor plasma. Antiplatelet antibody was not detected in any patient, and fibrinogen degradation products were either in the normal range or slightly raised.
Discussion
Infectious mononucleosis is a good model for the investigation of platelet-virus interaction, as it presents a definable population of patients in which a spectrum of quantitative platelet abnormalities can be found. This study shows that reduced platelet aggregation and impaired release of platelet factors III and IV are fairly common in patients with infectious mononucleosis which is uncomplicated but severe enough to require admission to hospital. In six studied in convalescence the platelet function was normal and the platelet count was significantly higher than it had been in the acute phase.
The pathogenesis of the platelet defect could not be determined from these studies. Known depressants of platelet function, such as antiplatelet antibody ) and fibrin degradation products (Merskey et al., 1969) were not detected. Incubation of normal platelet-rich plasma with platelet-poor plasma from patients with infectious mononucleosis and abnormal platelet function did not induce abnormal platelet function. Possible mechanisms would include virus uptake and platelet damage, as suggested by ultrastructural studies (Danon et al., 1959) , or altered cell behaviour due to a virus-directed membrane-associated protein (Roizman and Spear, 1971) . Alternatively, an immune response stimulated by the virus could cause platelet damage as a result of antibody directed against a virus-platelet complex, or from adsorption of immune complexes to the platelet membrane.
Immune complexes aggregate platelets (Luscher, 1970 ) and platelet aggregation has been used, in the presence of antigen, as a test for antibody in viral infections (Myllyla et al., 1969) . Thus it is possible that abnormal platelet function reflects a defect induced by non-specific immune complexes and that this defect determines premature platelet destruction and thrombocytopenia. 9  57  25  63  65  50  40  50  40  80  23  25  26  30  33  50  66  73  80  20  45-95 Platelet Aggregation (C,') Ristocetin   17  65  11  70  35  82  5  75  34  55  30  90  20  5  25  15  39  10   0   73  12  8  35-95   Adrenaline   15  50  2  50  20  73  15  17  38  10  45  80  30  8  5  10  13  15  6  10  18  8  20-95   Thrombin   15  50  5  25  17  50  5  45  38 abnormal platelet function. This is unlikely to be a significant factor in the series because of the different pattern of abnormality (Marcus, 1969) and the presence of abnormal function in patients who had not taken aspirin.
The higher platelet count and normal platelet function found in six patients studied in convalescence suggests that abnormal platelet function may reflect a platelet lesion predisposing to platelet destruction. Megakaryocyte hyperplasia in bone marrow smears from patients with uncomplicated infectious mononucleosis and mild thrombocytopenia (Boyd and Reid, 1968) supports the concept that platelet destruction determines thrombocytopenia in infectious mononucleosis. As thrombocytopenia occurs in about half of the patients with infectious mononucleosis at some stage of disease (Carter, 1965; Cantow and Kostinas, 1966) , increased platelet removal would occur in most patients. That intracorpuscular lesions can determine premature platelet destruction has been well established (Murphy et al., 1969) .
The relationship of abnormal platelet function to the rare complication of thrombocytopenic purpura is less clear. In several patients studied with thrombocytopenia complicating specific viral infections, very short isologous platelet survival indicated an antiplatelet factor. One of these patients had transient abnormalities of platelet function on recovery , suggesting a possible link with the more common asymptomatic form of thrombocytopenia. However, because of the rarity of thrombocytopenic purpura, other mechanisms could be involved in determining very low platelet counts. A second consequence of abnormal platelet function is impaired haemostasis, and such defects may account for the purpura occasionally seen in patients with only mild to moderate thrombocytopenia in infectious mononucleosis (Schumacher and Barcay, 1962) .
The role of abnormal platelet function in determining the outcome of virus-platelet interaction in other infections is not known. It is of interest, however, that a patient with rubella had similar platelet abnormalities , suggesting that abnormal platelet function may occur in a number of virus infections. It should be stressed, therefore, that with the widespread use of tests of platelet function, exclusion of recent viral infection should be made before abnormalities are attributed to other factors or congenital disorders. Finally, relapse in idiopathic thrombocytopenic purpura is often precipitated by virus infection. In this condition platelet abnormalities may persist in remission and an added defect induced by virus infection may lead to an exacerbation of purpura.
Introduction
We have previously reported that blood clotting tests, including specific factor VII and X assays, became accelerated in women taking conventional oestrogen/progestogen oral contraceptives (Thomson and Poller, 1965; Poller and Thomson, 1966) . These changes became significant from the third cycle of administration. When two oral contraceptives of varying hormone content -that is, Norinyl-1 and Ortho-Novin-were compared it seemed that the changes in clotting factor response were similar during the first nine months covered by our report (Poller et al., 1968) . We stated, however, that longer study was required to eliminate the possibility of gradual cumulative effects.
The present study is a follow-up of the same two groups of
